BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23587029)

  • 1. In-treatment HDL cholesterol levels and development of new diabetes mellitus in hypertensive patients: the LIFE Study.
    Okin PM; Hille DA; Wiik BP; Kjeldsen SE; Lindholm LH; Dahlöf B; Devereux RB
    Diabet Med; 2013 Oct; 30(10):1189-97. PubMed ID: 23587029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
    Okin PM; Hille DA; Wachtell K; Kjeldsen SE; Julius S; Devereux RB
    Blood Press; 2020 Oct; 29(5):319-326. PubMed ID: 32586143
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
    Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
    J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
    Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
    Okin PM; Bang CN; Wachtell K; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
    Circ Arrhythm Electrophysiol; 2013 Apr; 6(2):243-51. PubMed ID: 23403268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
    Ariansen I; Reims HM; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Kjeldsen SE; Dahlöf B; Wachtell K
    Blood Press; 2012 Feb; 21(1):6-11. PubMed ID: 22070095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
    Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
    J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
    Okin PM; Kjeldsen SE; Julius S; Hille DA; Dahlöf B; Edelman JM; Devereux RB
    Eur Heart J; 2010 Sep; 31(18):2271-9. PubMed ID: 20601389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
    Søraas CL; Wachtell K; Okin PM; Dahlöf B; Devereux RB; Tønnessen T; Kjeldsen SE; Olsen MH
    Blood Press; 2010 Jun; 19(3):145-51. PubMed ID: 20429689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
    Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
    J Hypertens; 2012 Apr; 30(4):802-10; discussion 810. PubMed ID: 22343536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.
    Gupta AK; Dahlof B; Dobson J; Sever PS; Wedel H; Poulter NR;
    Diabetes Care; 2008 May; 31(5):982-8. PubMed ID: 18235048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of electrocardiographic left ventricular hypertrophy to decreased serum potassium.
    Okin PM; Kjeldsen SE; Lindholm LH; Dahlöf B; Devereux RB
    Blood Press; 2012 Jun; 21(3):146-52. PubMed ID: 22243363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.
    Okin PM; Kamel H; Kjeldsen SE; Devereux RB
    J Hypertens; 2016 Sep; 34(9):1831-7. PubMed ID: 27254312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Eur J Heart Fail; 2011 Apr; 13(4):384-91. PubMed ID: 21239405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes.
    Zoppini G; Targher G; Chonchol M; Perrone F; Lippi G; Muggeo M
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):580-6. PubMed ID: 19196499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.